Emtricitabine / tenofovir disoproxil Alternatives Compared
| Emtricitabine / tenofovir disoproxil | Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide) | Descovy (emtricitabine / tenofovir alafenamide) |
|
|---|
| Emtricitabine / tenofovir disoproxil | Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide) | Descovy (emtricitabine / tenofovir alafenamide) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Pre-Exposure Prophylaxis of HIV, HIV Infection, Nonoccupational Exposure, Occupational Exposure. Emtricitabine / tenofovir disoproxil may also be used for purposes not listed in this... View more |
Prescription only
Biktarvy is a combination tablet that contains three antiviral agents which may be used to treat HIV-1 in adults and children weighing more than 25kg (55lb). It is generally well-tolerated and the... View more |
Prescription only
Prescribed for HIV Infection, Pre-Exposure Prophylaxis of HIV. Descovy may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Emtricitabine / tenofovir disoproxil | More about Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide) | More about Descovy (emtricitabine / tenofovir alafenamide) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Emtricitabine / tenofovir disoproxil has an average rating of 5.9 out of 10 from a total of 43 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 37% reported a negative effect. |
Biktarvy has an average rating of 7.2 out of 10 from a total of 226 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 19% reported a negative effect. |
Descovy has an average rating of 7.4 out of 10 from a total of 22 ratings on Drugs.com. 68% of reviewers reported a positive effect, while 18% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
View all Biktarvy side effects |
View all Descovy side effects |
|||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Biktarvy prices |
View all Descovy prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| AccessPak for HIV PEP Basic, Truvada |
N/A |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
25.7 hours |
180 hours |
25.7 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 249 drugs are known to interact with Emtricitabine / tenofovir disoproxil:
|
A total of 446 drugs are known to interact with Biktarvy:
|
A total of 249 drugs are known to interact with Descovy:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
August 02, 2004 |
February 07, 2018 |
April 04, 2016 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.